P2Y12 Inhibitors
8 drugsAbout P2Y12
The P2Y12 receptor is a G protein-coupled receptor activated by adenosine diphosphate (ADP) that plays a key role in platelet aggregation and blood clot formation. Excessive platelet aggregation can lead to thrombotic events, such as heart attack and stroke. Thus, P2Y12 is a crucial target in cardiovascular medicine.
Human genetic studies provide strong validation for P2Y12 as a therapeutic target, with variants linked to platelet-type bleeding disorder 8 (score 0.85) and Nizon-Isidor syndrome (score 0.82). Loss-of-function variants are associated with increased risk of platelet disorders, suggesting activation of P2Y12 may be beneficial.
P2Y12 is targeted by 8 FDA-approved small molecule drugs, including PRASUGREL, TICAGRELOR (Brilinta), and KENGREAL. These drugs, developed by companies like AstraZeneca and Aurobindo Pharma, are vital in preventing and treating cardiovascular diseases by inhibiting ADP-mediated platelet activation.
P2Y12 Genetic Evidence Strong
Genetic evidence strongly supports P2Y12's role in platelet disorders, with a max genetic score of 0.85.
Strong genetic support suggests that clinical trials targeting P2Y12 have a higher likelihood of success.
💡 Why activation?
- • Loss-of-function variants increase disease risk (OR > 1) — restoring function may help
- • 100% directional consistency across 2 traits
- • Strong signal in hematologic disease, genetic, familial or congenital disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
14 totalGWAS and other genetic studies link P2RY12 to 14 diseases.
Loss-of-function causes disease; activation may help
🔗 Colocalization Evidence 4 strong
max H4: 1.00eQTL/pQTL signals for P2RY12 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top P2Y12 Drugs
Eight companies have approved drugs targeting P2Y12, including Aurobindo Pharma and AMNEAL.
The presence of multiple players suggests a competitive market, requiring strong differentiation for new entrants.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| TICAGRELOR | Dr. Reddy's | 2018 | 7 |
| PRASUGREL HYDROCHLORIDE | UNICHEM | 2023 | 5 |
| EFFIENT | COSETTE | 2009 | 5 |
| KENGREAL | CHIESI | 2015 | 2 |
| CANGRELOR | MSN | 2025 | 2 |
P2Y12 Drug Modality Landscape
Modalities
Routes of Administration
P2Y12 is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
P2Y12 Clinical Trials 518 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on P2Y12. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 89 | 80 | 7 | 2 | 92% |
| Phase 2 | 64 | 51 | 6 | 7 | 89% |
| Phase 3 | 111 | 71 | 17 | 22 | 81% |
| Phase 4 | 254 | 194 | 27 | 33 | 88% |
Top Sponsors
By Modality
Top Conditions
P2Y12 Drug Approval Timeline (1997 - 2025)
The first P2Y12-targeting drug was approved in 1997, with the most recent approval in 2025.
The continued approvals over 29 years indicate sustained interest and potential for further innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 8 companies competing
- • Market share by company
Full Drug Portfolio
- • All 8 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 8-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 271 (50 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on P2Y12. A trial counts if an approved drug acting on P2Y12 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.